GLOBAL MICROCAP R

MONTHLY REPORT DECEMBER 31, 2024



Global Microcaps

Bench.

ISIN LU1329694266

-0.6% +14.4% Volatility 1 year

Bench

+12.8%





Bench.

Augustin LECOQ

COLOMBAN

Europe's stock markets ended slightly lower in December, once again penalised by hesitation as investors wait to see what happens when Donald Trump takes office. The ECB cut its key interest rates by 25 basis points, as expected, while the Fed delivered a rather cautious message about interest rate cuts going forward given the strength of the US economy. China's government announced further economic stimulus measures, but the market is still waiting for more concrete action.

The MSCI World index shed -0.7% over the month and the MSCI World Smallcap index -4.1%, while the MSCI World Microcap index gained +0.5%. The fund underperformed its benchmark index, with 186 of its 338 stocks losing ground. The top contributors included Personalis (+49%), after Merck increased its stake in the firm to 16.6%, Daiwa Cycle (+45%), whose results greatly exceeded expectations, and Redwire (+20%), which continues to enjoy excellent momentum. At the other end of the spectrum, AudioEye (-42%) plummeted after announcing that its chairman and CEO had placed shares in the company's stock, and CHROMADEX (-30%) corrected after having delivered an excellent performance.

The main portfolio movements included our decision to exit from Vita Coco, after it exceeded our market capitalisation threshold of €2bn, and from Profire Energy, Beenos and Equals Group, which all received takeover bids. Meanwhile, we initiated positions in Cembre, an Italian manufacturer of components for electrical connectors, and in Kraken Robotics, a Canadian manufacturer of sensors and components for autonomous seabed mapping and exploration drones. We also moved back into Nomura Micro Science, a Japanese designer of ultrapure water treatment systems, whose GARP profile looks attractive again following the stock's correction.

Main transactions over the month

(+) CEMBRE SPA

(-) VITA COCO

(+) NOMURA MICRO-SCIE...

(-) PROFORE ENERGY

(+) KRAKEN ROBOTICCS

(-) EQUALS GROUP

(+) New holding (-) Sale

Major contributors/detractors over the month (%)

 PERSONALIS INC
 +0.2
 AUDIOEYE INC
 -0.2

 DAIWA CYCLE CO LTD
 +0.1
 AQUESTIVE THERA...
 -0.1

 BEENOS INC
 +0.1
 CHROMADEX CORP
 -0.1

Mandarine Global Microcap invests in the smallest global market capitalisations, applying a quantitative screening filter followed by fundamental stock analysis, designed to detect those stocks which offer the most favourable risk/return profile.

PERFORMANCES AND RISKS

The data presented relates to past periods, past performance is not an indicator of future results. Statistical indicators are calculated on a weekly basis.

Benchmark: MSCI World Microcap NR EUR



Annual performances Fund Bench +26.9 +25.2 +25.2 +14.4 +12.8 15% +4.9 +3.1 _15% -30% 2019 2020 2021 2022 2023 2024

Rolling / annualized performances

	Rolling performances				Annualized performance				
	1 month	YTD	1 year	3 years	5 years	Inception	3 years	5 years	Inception
Fund	-0.6%	+14.4%	+14.4%	-0.2%	+40.8%	+90.6%	-0.1%	+7.1%	+7.9%
Bench.	+0.5%	+12.8%	+12.8%	-4.2%	+35.1%	+82.3%	-1.4%	+6.2%	+7.3%
Diff.	-1.1%	+1.6%	+1.6%	+4.0%	+5.7%	+8.3%	+1.3%	+0.9%	+0.6%
Quartile*	1	2	2	3	2	2			

EAA Fund Global Small/Mid-Cap Equity

Risk indicators

	Fund volatility	Benchmark volatility	Tracking error	Information ratio	Sharpe ratio
1 year	12.4%	12.2%	3.1%	0.5	0.9
3 years	13.0%	12.3%	3.3%	0.4	-0.2

MANDARINE

GLOBAL MICROCAP R



PORTFOLIO STRUCTURE

Main holdings						
VESYNC CO LTD	0.4%	Cons.Discretionary / United-St				
MYOMO INC	0.4%	Health Care / United-States				
COASTAL FINANCIAL CORP/WA	0.4%	Financials / United-States				
CEWE COLOR HOLDING AG	0.4%	Industrials / Germany				
SIMILARWEB LTD	0.4%	Technology / Israel				
GRAHAM CORP	0.4%	Industrials / United-States				
IRADIMED CORP	0.4%	Health Care / United-States				
EVS BROADCASTING EQUIP	0.4%	Technology / Belgium				
HIBINO CORP	0.4%	Technology / Japan				
TDC SOFT INC	0.4%	Technology / Japan				

Sector		Country
Industrials	20.4%	Japan
Technology	15.6%	United-Sta
Financials	13.8%	Great-Brita
Cons. Discretionary	13.4%	Australia
Health Care	13.3%	Canada
Materials	6.5%	Sweden
Cons.Staples	5.3%	France
Communication serv.	3.9%	Israel
Real Estate	3.5%	Germany
Energy	2.9%	Norway
Utilities	1.0%	China
Cash & Others	0.5%	Italy
		Belgium

Country	
Japan	26.9%
United-States	26.1%
Great-Britain	8.1%
Australia	6.9%
Canada	5.0%
Sweden	4.3%
France	3.1%
Israel	2.9%
Germany	2.3%
Norway	2.0%
China	1.6%
Italy	1.6%
Belgium	1.1%
Other Country	7.6%
Cash & Others	0.5%

FUND PROFILE

Key figures at December 31 2024

Asset under management	25.6M€
Equity exposure	99.6%
Number of holdings	338
Active share	93.6%
EPS growth (Next 12 M./Last 12 M.)	+15.3%
PE (Next 12 Months)	13.0x




152 Carbon footprint

Capitalisation



0.5%

Currency



CHARACTERISTICS

ISIN	Bloomberg code	Inception of the fund	Shareclass inception
LU1329694266	MGMCRAE LX Equity	12/07/2016	12/07/2016
Legal Status	Shareclass currency	Investment horizon	Management company
Sicav Lux.	EUR	5 years	Mandarine Gestion
Depositary	Valuation	Cut-Off	Settlement
BNP Paribas	Daily	13h00	D+3 (NAV D+1)
Management Fee	Performance Fee	Initial charge	Redemption Fee
1.95%	20% of the outperformance over the benchmark	2.00%	0%



Mandarine Gestion 30 avenue Kléber | 75016 Paris www.mandarine-gestion.com

DISCLAIMER

The purpose of this document is to present, for information purposes only, the characteristics of Mandarine Gestion products. It in no manner constitutes a sale or subscription offer. The indices cited in this document are based on net dividends reinvested ("NR"). The described performances do not take into account fees and costs potentially charged in connection with the subscription or redemption of fund units. This document has been drawn up for information purposes only and does not constitute an offer or personalised recommendation or a solicitation to subscribe to this product. The information, opinions and analyses contained in this document do not have any contractual value. Only the information contained in the KIID and prospectus is legally binding. The prospectus is available on simple demand from Mandarine Gestion and is available on the www.mandarine.gestion.com website. Your money will be principally invested in financial instruments selected by the management company. These instruments will be subject to market fluctuations and uncertainties. Past performances do not guarantee future performances. Performances are notably not constant over time. The performance data mentioned in the document does not take into account fees and charges assessed in connection with the issue and redemption of units or shares and does not include taxes imposed by the country of residence of the client. The LOITS is exclusively destined for sale to residents of those countries in which the UCITS is registered. Sales in jurisdictions other than those countries in which the UCITS is registered are not authorised.

sale to residents of those countries in which the UCITS is registered. Sales in jurisdictions other than those countries in which the UCITS is registered are not authorised.

RISK PROFILE - RISKS ASSOCIATED WITH THE PRODUCT

Risk of capital loss, equity market risk, risk linked to the ownership of small and midcaps, interest rate risk, credit risk and discretionary management risk, and to a lesser extent emerging market risk, counterparty risk and exchange rate risk. The descriptions and details are included in the complete prospectus of the UCITS. Investors are invited to read the prospectus in order to obtain detailed information regarding the risks to which the fund is exposed prior to any investment decision. This product does not offer any guarantee as to returns or the capital invested, which may not be entirely returned.



^{*}Tonnes of CO2e/M€ invested, Direct (scope 1-2) + First tier indirect